This study evaluates the effectiveness of superselective transcatheter arterial chemoembolization (TACE) using a bleomycin–lipiodol emulsion in treating giant hepatic hemangiomas. A retrospective review included 31 patients with a mean age of 53 ± 10.42 years who underwent TACE from December 2014 to October 2022, with follow-up imaging examinations to assess outcomes. Technical success was defined as successful embolization of all feeding arteries, and clinical success was defined as a reduction in hemangioma volume by 50% or more on follow-up imaging. This study observed a 100% technical success rate. Post-embolization syndrome was common, and two cases of asymptomatic hepatic artery dissection were noted. Clinical success was achieved in 80.6% of patients, with significant volume reduction observed in the majority. Conclusively, superselective transcatheter arterial chemoembolization with bleomycin–lipiodol emulsions is presented as a viable and effective treatment option for giant hepatic hemangiomas. With no procedure-related mortality and significant volume reduction in most cases, this method offers a promising alternative to surgical intervention. This study’s findings suggest a need for further exploration and validation in larger-scale prospective studies.
本研究评估了博来霉素-碘油乳剂超选择性经导管动脉化疗栓塞术（TACE）治疗巨大肝血管瘤的疗效。回顾性分析纳入了2014年12月至2022年10月期间接受TACE治疗的31例患者，平均年龄为53±10.42岁，并通过随访影像学检查评估治疗效果。技术成功定义为所有供血动脉成功栓塞，临床成功定义为随访影像显示血管瘤体积缩小50%及以上。本研究观察到技术成功率为100%。栓塞后综合征较为常见，并发现两例无症状肝动脉夹层病例。80.6%的患者实现临床成功，大多数患者血管瘤体积显著缩小。结论表明，采用博来霉素-碘油乳剂的超选择性经导管动脉化疗栓塞术是治疗巨大肝血管瘤可行且有效的方案。该方法无手术相关死亡，且在多数病例中实现显著体积缩小，为外科手术干预提供了具有前景的替代选择。本研究结果提示，未来需要通过更大规模的前瞻性研究进一步探索和验证该疗法。
肿瘤(癌症)患者之家